Company Profile

Tepha Inc
Profile last edited on: 9/29/2021      CAGE: 417T3      UEI: NB1JDAYJLSH3

Business Identifier: New class of absorbable biomaterials for use in surgical procedures
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

99 Hayden Avenue East Wing Suite 360
Lexington, MA 02421
   (781) 357-1700
Location: Multiple
Congr. District: 05
County: Middlesex

Public Profile

In July 2021 it was announced that BD (Becton, Dickinson and Company) (NYSE: BDX) had acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology. SBIR-involved in its early days but not recently, Tepha had been a spin-off of Metabolix, Inc. - itself an SBIR-involved firm - Tepha had been privately held with technology based on the production of pha polymers, and their application in bio-absorbable medical devices. The Company is the exclusive licensee of Metabolix's transgenic pha production technology for in vivo use. The licensed technology includes proprietary methods of production, polymer compositions, methods of purification, as well as medical applications of the pha polymers. Tepha is engaged in the development of a new range of bioabsorbable medical devices for therapeutic applications. The Company has licensed and is applying a patented core technology which allows it to produce bioabsorbable polymers suitable for use in a wide range of implantable products to treat humans with defective tissues and organs. The Company's polymers are produced by a new transgenic production technology which accesses an extensive library of more than one hundred monomer building blocks. By careful selection of these different building blocks, Tepha is able to tailor the properties of its polymers to specific medical applications. Using this polymer design space, it is possible to engineer new medical materials, that cannot be produced by any other means, that have desirable mechanical properties, different rates of bioabsorption, and even produce polymers that can be derivatized with other chemistries. Tepha's polymers evaluated for use in an extensive range of medical devices, including guided tissue regeneration barriers, orthopedic fixation devices, and general surgical products, like sutures, staples, and meshes. Subsequent products included degradable stents, tissue engineering scaffolds, drug delivery systems, ultrasound agents, nerve guides, and medical adhesives.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 2 NIH $849,998
Project Title: A new absorbable mesh for hernia repair
2006 1 NIH $100,000
Project Title: Arthroscopic rotator cuff repair device
2005 1 NIH $100,000
Project Title: A new absorbable antimicrobial bone graft substitute
2005 1 NIH $131,346
Project Title: A New Surgical Mesh for Pelvic Floor Reconstruction
2005 2 NIH $810,994
Project Title: Biopolymer fiber as a bioabsorbable monofilament suture

Key People / Management

  Andrew Joiner -- President, CEO & Director

  Connie Garrison -- SVP, Regulatory, Clinical and Quality Systems

  John Hartnett -- Executive Vice President, & COO

  Lois Lombardivice -- Vice President, Galatea

  David P Martin -- Chief Scientific Officer and Sr. Vice President of Research & Development

  Said Rizk -- Chief Innovations Officer and Sr. Vice President of Manufacturing and Process Te

  Ian Vawter -- Chief Financial Officer